Janney Montgomery Scott LLC raised its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 34.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 120,550 shares of the exchange traded fund’s stock after purchasing an additional 30,819 shares during the quarter. Janney Montgomery Scott LLC’s holdings in SPDR S&P Biotech ETF were worth $15,398,000 at the end of the most recent quarter.
Several other institutional investors also recently made changes to their positions in the stock. AQR Capital Management LLC grew its stake in SPDR S&P Biotech ETF by 77.1% during the first quarter. AQR Capital Management LLC now owns 4,978 shares of the exchange traded fund’s stock worth $404,000 after buying an additional 2,167 shares during the period. Marshall Wace LLP lifted its holdings in shares of SPDR S&P Biotech ETF by 102.3% during the 2nd quarter. Marshall Wace LLP now owns 4,023 shares of the exchange traded fund’s stock valued at $334,000 after acquiring an additional 179,029 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of SPDR S&P Biotech ETF during the 2nd quarter valued at $260,000. Ameriprise Financial Inc. boosted its position in SPDR S&P Biotech ETF by 123.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 872,796 shares of the exchange traded fund’s stock worth $72,542,000 after purchasing an additional 481,408 shares during the period. Finally, EP Wealth Advisors LLC boosted its position in SPDR S&P Biotech ETF by 3.7% during the 2nd quarter. EP Wealth Advisors LLC now owns 5,379 shares of the exchange traded fund’s stock worth $446,000 after purchasing an additional 193 shares during the period.
SPDR S&P Biotech ETF Price Performance
Shares of NYSEARCA XBI opened at $158.25 on Wednesday. SPDR S&P Biotech ETF has a 1-year low of $82.04 and a 1-year high of $160.01. The company has a market capitalization of $10.10 billion, a price-to-earnings ratio of 11.47 and a beta of 0.85. The business has a 50-day moving average of $136.09 and a 200-day moving average of $129.25.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Read More
- Five stocks we like better than SPDR S&P Biotech ETF
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
